JAGX
Price
$4.25
Change
-$0.24 (-5.33%)
Updated
Oct 1, 11:14 AM (EDT)
Capitalization
3.13M
48 days until earnings call
Intraday BUY SELL Signals
VKTX
Price
$30.85
Change
-$1.75 (-5.37%)
Updated
Oct 1, 04:06 PM (EDT)
Capitalization
4.11B
27 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

JAGX vs VKTX

JAGX vs VKTX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
JAGX vs. VKTX commentary
Oct 01, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAGX is a Hold and VKTX is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
JAGX vs VKTX: Fundamental Ratings
JAGX
VKTX
OUTLOOK RATING
1..100
9686
VALUATION
overvalued / fair valued / undervalued
1..100
8
Undervalued
52
Fair valued
PROFIT vs RISK RATING
1..100
10077
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
9856
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
33n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

JAGX's Valuation (8) in the Pharmaceuticals Generic industry is somewhat better than the same rating for VKTX (52) in the Biotechnology industry. This means that JAGX’s stock grew somewhat faster than VKTX’s over the last 12 months.

VKTX's Profit vs Risk Rating (77) in the Biotechnology industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that VKTX’s stock grew similarly to JAGX’s over the last 12 months.

VKTX's SMR Rating (98) in the Biotechnology industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that VKTX’s stock grew similarly to JAGX’s over the last 12 months.

VKTX's Price Growth Rating (56) in the Biotechnology industry is somewhat better than the same rating for JAGX (98) in the Pharmaceuticals Generic industry. This means that VKTX’s stock grew somewhat faster than JAGX’s over the last 12 months.

VKTX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that VKTX’s stock grew similarly to JAGX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
JAGXVKTX
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 15 days ago
80%
Bullish Trend 9 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
COMPARISON
Comparison
Oct 01, 2026
Stock price -- (JAGX: $4.50 vs. VKTX: $32.60)
Brand notoriety: JAGX and VKTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JAGX: 48% vs. VKTX: 184%
Market capitalization -- JAGX: $3.13M vs. VKTX: $4.11B
JAGX [@Biotechnology] is valued at $3.13M. VKTX’s [@Biotechnology] market capitalization is $4.11B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JAGX’s FA Score shows that 1 FA rating(s) are green while VKTX’s FA Score has 0 green FA rating(s).

  • JAGX’s FA Score: 1 green, 4 red.
  • VKTX’s FA Score: 0 green, 5 red.
According to our system of comparison, JAGX is a better buy in the long-term than VKTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JAGX’s TA Score shows that 4 TA indicator(s) are bullish while VKTX’s TA Score has 5 bullish TA indicator(s).

  • JAGX’s TA Score: 4 bullish, 5 bearish.
  • VKTX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, VKTX is a better buy in the short-term than JAGX.

Price Growth

JAGX (@Biotechnology) experienced а -49.49% price change this week, while VKTX (@Biotechnology) price change was -21.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.64%. For the same industry, the average monthly price growth was -11.26%, and the average quarterly price growth was +0.32%.

Reported Earning Dates

JAGX is expected to report earnings on Nov 18, 2026.

VKTX is expected to report earnings on Oct 28, 2026.

Industries' Descriptions

@Biotechnology (-2.64% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
JAGX
Daily Signal:
Gain/Loss:
VKTX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
AIYY7.500.29
+4.02%
YieldMax AI Option Income Strategy ETF (AIYY)
AGGH18.930.07
+0.37%
Simplify Aggregate Bond ETF (AGGH)
ISRA66.670.08
+0.12%
VanEck Israel ETF (ISRA)
ARMY23.93N/A
N/A
Tema ETF Trust
EEMV74.05-0.67
-0.90%
iShares MSCI Emerging Markets Min Vol Factor ETF (EEMV)

JAGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, JAGX has been loosely correlated with VKTX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if JAGX jumps, then VKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAGX
1D Price
Change %
JAGX100%
-15.41%
VKTX - JAGX
46%
Loosely correlated
+2.48%
FLNA - JAGX
42%
Loosely correlated
-4.19%
TCRT - JAGX
36%
Loosely correlated
-8.46%
MNOV - JAGX
35%
Loosely correlated
-12.76%
RNAZ - JAGX
31%
Poorly correlated
+3.07%
More